Targeting the Glutamatergic System to Treat Major Depressive Disorder: Rationale and Progress to Date

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.10, 2012-07, pp. : 1313-1333

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Resilience Dysregulation in Major Depressive Disorder: Focus on Glutamatergic Imbalance and Microglial Activation

Current Neuropharmacology, Vol. 16, Iss. 3, 2018-03 ,pp. : 297-307

Bentham Science Publishers

Access to resources Recommend Favorite

Important to identify and treat major depressive disorder in patients with coronary heart disease

Drugs & Therapy Perspectives, Vol. 26, Iss. 3, 2010-03 ,pp. : 18-21

Adis International

Access to resources Recommend Favorite

Selegiline Transdermal System: In the Treatment of Major Depressive Disorder

By Frampton James E. Plosker Greg L.

Drugs, Vol. 67, Iss. 2, 2007-01 ,pp. : 257-265

Adis International

Access to resources Recommend Favorite

Major Depressive Disorder and Magnetic Resonance Imaging: A Mini-Review of Recent Progress

Current Pharmaceutical Design, Vol. 24, Iss. 22, 2018-06 ,pp. : 2524-2529

Bentham Science Publishers

Access to resources Recommend Favorite

Vilazodone: In Major Depressive Disorder

By Frampton James E.

CNS Drugs, Vol. 25, Iss. 7, 2011-07 ,pp. : 615-627

Adis International

Access to resources Recommend Favorite